A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small UCLA clinical trial suggests.

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in its phase 1 trial. Researchers at the University of California said 21 out of 25 patients generated an immune response to cancer cells.

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer,